US equities |
NVDA $240.57 ▲+0.70% SPCX $173.77 ▲+1.57% MU $1,064.55 ▲+0.06% MRVL $281.51 ▲+3.78% AMD $656.02 ▲+3.84% INTC $114.37 ▼-1.57% SNDK $1,669.91 ▼-2.01% AVGO $377.19 ▲+4.05%
FinancialContent

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

5.450 +0.150 (+2.83%)
Delayed Quote Updated: 12:54 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Via FinancialNewsMedia
News headline image
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin ↗
CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma... 
Via Benzinga
News headline image
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin ↗
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. 
Via Talk Markets
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >